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ORIGINAL ARTICLE
Allele-specific loss and transcription of the miR-15a/16-1
cluster in chronic lymphocytic leukemia
A Veronese1,2, F Pepe1,2, J Chiacchia1, S Pagotto1,2, P Lanuti3, S Veschi1,2, M Di Marco2, A D’Argenio1, I Innocenti4,
B Vannata4, F Autore4, M Marchisio3, D Wernicke5, F Verginelli1, G Leone4, LZ Rassenti6,7, TJ Kipps6,7, R Mariani-Costantini1,2,
L Laurenti4, CM Croce5,7 and R Visone1,2
Deregulation of the miR-15a/16-1 cluster has a key role in the pathogenesis of chronic lymphocytic leukemia (CLL), a clinically
heterogeneous disease with indolent and aggressive forms. ThemiR-15a/16-1 locus is located at 13q14, the most frequently deleted
region in CLL. Starting from functional investigations of a rare SNP upstream the miR cluster, we identified a novel allele-specific
mechanism that exploits a cryptic activator region to recruit the RNA polymerase III for miR-15a/16-1 transcription. This regulation
of the miR-15a/16- locus is independent of the DLEU2 host gene, which is often transcribed monoallellically by RPII. We found that
normally one allele of miR-15a/16-1 is transcribed by RNAPII, the other one by RNAPIII. In our subset of CLL patients harboring
13q14 deletions, exclusive RNA polymerase III (RPIII)-driven transcription of the miR-15a/16-1 was the consequence of loss of the
RPII-regulated allele and correlated with high expression of the poor prognostic marker ZAP70 (P¼ 0.019). Thus, our findings point
to a novel biological process, characterized by double allele-specific transcriptional regulation of the miR-15a/16-1 locus by
alternative mechanisms. Differential usage of these mechanisms may distinguish at onset aggressive from indolent forms of CLL.
This provides a basis for the clinical heterogeneity of the CLL patients carrying 13q14 deletions.
Leukemia (2015) 29, 86–95; doi:10.1038/leu.2014.139
INTRODUCTION
Chronic lymphocytic leukemia (CLL), the most common form
of adult leukemia in the Western world,1 is characterized by a
heterogeneous clinical course, essentially dividable into indolent
and aggressive forms.2 Deletion of 13q14 is the most frequent
genetic aberration associated with CLL3–6 and represents an
early disease-associated event.7–9 Although generally considered a
favorable prognostic factor,10,11 CLL patients bearing this deletion
show heterogeneous clinical outcomes, that can be partially
stratified according to 13q deletion subtype.12,13
In vitro and in vivo studies14–17 conclusively demonstrate that
the miR-15a/16-1 cluster, located at 13q14, controls cell cycle and
apoptosis in B cells and that deregulation of these miRNAs
contributes to the pathogenesis of CLL. The 13q14 deletion is one
of the main causes of the downregulation of the miR-15a and
miR-16-1 in CLL, although it should be considered that miR-15a/
16-1 expression shows allelic imbalances,18,19 and that TP53
mutations or deletions affect the transcription and/or maturation
of the primiR.4,15,20 This cluster is located within the DLEU2 gene,
whose expression is controlled by epigenetic mechanisms
entailing a monoallelic expression in lymphoid cells from both
CLL patients and healthy controls.19 This occurs for the majority of
the genes located at this region, suggesting that the miR-15a/16-1
cluster could be regulated in the same way.
In the present work, we studied the region immediately
upstream the miR-15a/16-1 cluster. We first investigated
a functional SNP, rs115069827, whose minor allele abrogates
the maturation of primiR-15a/16-1. We then demonstrated
that the region surrounding the SNP functions as an activator of
transcription by both RNA polymerase II and RPIII. The RPIII-driven
transcription of primiR-15a/16-1 from this cryptic activator is allele-
specific and, in our CLL patients, results dominant in the cases
with 13q14 deletions that are characterized by high expression
of ZAP70, a predictor of poor prognosis.
MATERIALS AND METHODS
Primary cells, cell lines and cell culture
CLL samples were obtained from patients enrolled in the CLL Research
Consortium and ‘Policlinico Agostino Gemelli’, ‘Universita` Cattolica del
Sacro Cuore’, Rome, on written informed consent in accordance with the
Declaration of Helsinki. The study protocols were approved by the
Institutional Review Boards of The Ohio State University and the ‘Policlinico
Agostino Gemelli’. The participating institutions provided the clinical data
associated with each patient at the time of sample collection. Among
patients, there was a rare case of monozygotic twin sisters that share a
germline single nucleotide variation in ARLTS1.21 The samples were
analyzed to determine expression of ZAP70, immunoglobulin heavy chain
variable mutational status and karyotype, as previously described.22
Peripheral blood mononuclear cells (PBMC) were isolated by density
gradient centrifugation with Ficoll-PaquePlus (Amersham Biosciences,
Uppsala, Sweden). Cell lines WaC3CD5 (WAC),23 MEC-2, MEC-1,24
HEK293T, K562 (from ATCC) and CLL cells were cultured in RPMI1640,
supplemented with 10% fetal bovine serum of Australian origin, 2mmol/l
L-glutamine, 100 units/ml of penicillin and 100 units/ml streptomycin in a
humidified incubator containing 5% CO2 at 37 1C. All the cell lines were
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authenticated by short tandem repeat analysis (Promega, Fitchburg, WI,
USA, PowerPlex16HS) comparing the results with the on-line databases
(www.lgcstandards-atcc.org/en/STR_Database.aspx?slp=1; www.dsmz.de/
fp/cgi-bin/str.html; http://strdb.cogcell.org/) (Supplementary Table S5).
The STR profile of WaC3CD5 was not in the databases. MEC-1 and
MEC-2 cell lines, which originate from the same patient and share the same
STR profile, were authenticated by karyotype analysis (Supplementary
Table S5). The densities of cultured cells were maintained between 1 and
3million/ml. Epstein–Barr virus infection of CLL cells was conducted as
described by Doyle et al.25
Cell treatments, transfection and luciferase assay
The RNAPII inhibitor, a-amanitin (A2263 Sigma, St Louis, MO, USA) was
dissolved in bi-distilled sterile water and filtered by 0.2mm filter. The
experiments were performed by using growing doses of a-amanitin, that is,
1, 2, 3, 5, 10mg/ml on each point of 2000.000 cells/ml or 2 and 10 mg/ml on
each point of 500 000–1000 000 cells/ml. After 16 h, the cells were lysed in
700ml of Qiazol (Qiagen, Venlo, Netherlands) for the RNA extraction.
Transfection of DNA vectors (200–500ng/50 000 cells) in HEK293T was
performed with Lipofectamine2000 (Invitrogen, Carlsbad, CA, USA) in
accordance with the manufacturer’s procedures, whereas transfection of
MEC-1, MEC-2, WaC3CD5 and K562 was performed using the Amaxa
nucleofector (Lonza, Basel, Switzerland) according to the manufacturer’s
protocols (plasmids:3000 ng/1 000 000 cells; small interfering RNA 40 pmol/
1 000 000 cells). siPOLR3A (sc-90684), siPOLR3G (sc-43507) and small
interfering RNA -A as control (sc-37007) were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). The efficiency of transfection was
determined by cytofluorometry, messenger RNA expression and\or
fluorescence microscopy. After transfection of luciferase reporter vectors
(pGL3Ren-187_A and pGL3Ren-187_G), the luciferase assay was conducted
according to manufacturer’s dual luciferase assay protocol (Promega).
Cell staining for flow cytometry
Cell staining was performed as already reported.26,27 Briefly, 5 105 cells per
sample were washed, resuspended in 100ml of surface antibody mix (1ml/
sample of anti CD5-PE and 1ml/sample of anti-CD19-PECy5) and incubated
for 30min at 4 1C in the dark. Cells were washed and stored at 4 1C in the
dark until acquisition. Phycoerythrin-conjugated anti-CD5 (CD5-PE) and
PE-cyanin 5-conjugated anti-CD19 (CD19-PECy5) were purchased from
Becton Dickinson (BD, Franklin Lakes, NJ, USA). A FACSCantoII flow
cytometer, running with FACSDiVa software (BD), was used for cell
analysis; 10000 events for each sample were recorded. CompBeads (BD)
as well as the antibodies used in the assay, as single stained tubes, were
utilized to assess fluorescence compensation. Non-specific fluorescence was
evaluated using fluorescence minus one controls.27 Data were analyzed
using the softwares FACSDiVa (BD) and FlowJo (TreeStar, Ashland, OR, USA).
DNA extraction, sequencing and copy number variation
Genomic DNA was isolated from cell lines and PBMC from CLL samples by
standard treatment with Hirt’s solution in the presence of 200mg/ml of
proteinase K, followed by phenol/chloroform/isoamyl extraction and
ethanol precipitation. The DNA regions of interest were amplified with
primers detailed in Supplementary Table S4 and sequenced using the
BigDye Terminator v3.1 Cycle Sequencing Kit (Life Technologies, Waltham,
MA, USA) according to the manufacturer’s specification, with an ABI3130xl
Genetic Analyzer (Life Technologies). Copy number variation was
performed by real-time PCR using the TaqMan technology. Briefly, 10 ng
of DNA was amplified using specific primers and fluorescent probes and a
standard internal reference (TaqMan RNase P assay, Life Technologies)
Each sample was analyzed in triplicate on 7900HT Real-Time PCR system.
Each well was normalized to RNase P to obtain a DCt (2 (FAM dye Ct VIC dye Ct)),
and then the average DCt for each triplicate was calculated. All samples
were then normalized to a calibrator (eight DNA samples from healthy
patients) to determine DDCt. As the percentage of B-CLL cells could vary
among patients, samples where considered carrying 13q deletion if loss of
genetic material at the 13q chromosome region was X25% compared
with normal control.
RNA extraction and quantitative real-time PCR
RNA was extracted using the miRNeasy MicroKit (Qiagen), treated with the
RNase-Free DNase Set (Qiagen) according to the instructions of the
manufacturer and quantified with Nanodrop2000 (Thermo-Scientific,
Waltham, MA, USA). RNA quality was analyzed using the Experion RNA
HighSens Analysis Kit (Bio-Rad, Hercules, CA, USA). RNA quality indicator
was on a median average of 8.15. Gene sequences were from NCBI (http://
www.ncbi.nlm.nih.gov/), RNA sequences for 18S, DLEU2, were used into the
Universal ProbeLibrary (UPL) Assay Design Center software (https://
www.rocheappliedscience.com/sis/rtpcr/upl/index.jsp?id=uplct_030000) to
identify primers and UPL probes (Supplementary Table S4). Total RNA
(50–200ng) was retrotranscribed with High Capacity cDNA Reverse
Transcription Kit (Life Technologies). The primiR exogenous expression
was assessed with the SYBR green technology (Qiagen), while the
endogenous expression of the primiR was performed with TaqMan assay
(Life Technologies). To test DNAse treatment efficiency, cDNA synthesis
was performed without the enzyme reverse transcriptase (noRT-PCR).
MicroRNAs quantization was performed using stem loop RT primers
designed28 with a modification to include the UPL #21 sequence binding
site.29 UPL probe #21 was from UPL database (Roche Diagnostics, Basel,
Switzerland). Total RNA (50 ng) was retrotranscribed with TaqMan Micro-
RNA Reverse Transcription Kit (Life Technologies). Reactions were
incubated 30min at 16 1C, followed by pulsed RT of 60 cycles at 30 1C
for 30 s, 42 1C for 30 s and 50 1C for 1 s.30 Real-time PCRs were performed in
an Applied Biosystems 7900 instrument. MiRNA and messenger RNA levels
were measured using Ct (threshold cycle). Target amount, normalized to
an endogenous references 18S/RNU44 and relative to a calibrator, is given
by 2DDCt and/or 2DCt methods (Life Technologies).
RNA-binding protein immunoprecipitation
RIP was performed with Magna RIP kit (Millipore, Billerica, MA, USA)
according to the manufacturer’s instruction. Cells transfected with vectors
pCDF1070_A or pCDF1070_G were lysed and the RNA-associated proteins
were immunoprecipitated (IP) with anti-DROSHA (Novus Biologicals,
Littleton, CO, USA, NBP1-03349). The precipitated RNA was retrotran-
scribed and measured by quantitative real-time PCR (SYBR green, Qiagen)
and referenced to the non-IP control (Input). The Magna RIP kit does
not include a DNase step before RT-PCR, thus, given that our experi-
mental conditions required plasmid transfection, the evaluation of the
IP primiR-15a/16-1 was calculated taking into account plasmid conta-
mination: IP_(DROSHA_primiR)¼ (2-(Ct IP_DROSHA_primir-Ct INPUT_DROSHA_primir))/
(2-(Ct noRT_DROSHA_PrimiR-Ct INPUT_DROSHA_primir)).
Chromatin immunoprecipitation (ChIP)
ChIP was carried out with the Magna ChIP-A/G kit (Millipore) according to the
manufacturer’s instruction. Briefly, transfected K562 cells, treated with
formaldehyde, were sonicated after nuclear protein extraction. Nuclear extracts
were IP with anti-POL II (CTD4H8, Santa Cruz sc-47701), as positive control, and
anti-POL III (RPC32, Santa Cruz sc-28712). Specific DNA enrichment was
measured by real-time PCR (SYBR green, Qiagen) and referenced to the non-IP
control (Input). The experiments were performed in duplicate.
RESULTS
A single nucleotide variation upstream the miR-15a/16-1 cluster in
CLL patients
Because of the importance of the miR-15a/16-1 cluster in CLL, we
sequencedB1000 nucleotides around this genomic region in 249
DNA samples from PBMCs of CLL patients. We found A–G
heterozygosis (rs115069827) in DNA from two CLL patients,
CLL479 and CLL585 (Table 1, Supplementary Figure S1a). This
polymorphism is located within the region immediately upstream
Table 1. Heterozigosity of SNP rs115069827 and CNV for miR-15a/16-1
cluster in CLL479 and CLL585
Samples DNA
(PBMC)
DNA
(buccal
swab)
CNV miR-
15a-16-1
(PBMC)
CNV miR-
15a-16-1
(buccal swab)
CLL479 A/G A/G þ /þ þ /þ
CLL585 A/G A/G  / þ /þ
Abbreviations: CNV, copy number variation; PBMC, peripheral blood
mononuclear cells.
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of miR-15a (Figure 1). To complete the genetic analysis of these
samples, we confirmed germline heterozygosity of CLL479 and
CLL585 by analyzing DNA from buccal swab of the two patients.
The genomic region upstream the miR-15a/16-1 cluster acts as
its transcriptional activator and is not affected by the SNP
rs115069827
To determine whether the A–G SNP affected miR-15a/16-1
expression, we studied the genomic region encompassing the
variant allele. At first we speculated that this region could act
as transcriptional activator of the candidate miRNAs and that the
G and A variants differently influence miRNAs expression. To test
this, PCR-amplified fragments (187 bp), comprising either the A or
the G variants, were obtained from CLL479 and subcloned into a
modified version of the pGL3 basic vector including Renilla
luciferase as internal control for transfection efficiency. HEK293
and MEC-02 cells were transiently transfected with the generated
constructs (pGL3Ren-187_A and pGL3Ren-187_G). The results
indicated strong promoter activity of the subcloned fragments,
with no differences between the two variants (Figure 2a).
To assess the primiR expression, we then cloned a broad region
(1070 bp), including the entire cluster and the putative promoter
with either the A or the G variant (Figure 2b), in the lentiviral
expression vector lacking the constitutive promoter (pCDF1070_A
and pCDF1070_G). The vectors were transiently transfected into
K562 and WAC cells. We noted a threefold induction of exogenous
primiR-15a/16-1 expression compared with the controls (empty
vector), irrespective of the variant. The results were more
convincing in the WAC cell line, in which only exogenous primiR
was detectable, as these cells lack both alleles of the miR-15a/16-1
cluster locus. The primiR was normalized on GFP expression, to
exclude differences in transfection efficiency, and the effective
DNase treatment was tested by PCR in the RNA samples
(noRT, Supplementary Figure S2).
These findings suggest that the regulation of the primiR-15a/
16-1 can occur independently of its host gene DLEU2.
To corroborate these results, we correlated the expression of
miR-15a and miR-16 with that of DLEU2 in two subgroups of
patients with different CLL karyotype and prognosis (13q deletion
Figure 1. Schematic representation of the DLEU2/miR-15a/16-1 locus. (a) Genomic structure of the DLEU2/miR-15a/16-1 locus from the
reference NC000013 genomic sequence (NCBI). Telomeric (Tel) and centromeric (Cen) position, genomic positions and structure of DLEU2,
FLJ31945, DLEU1, miR-15a/16-1, KCNRG and TRIM13, exons (black bars), start site and direction (arrows), the SNP rs115069827 (red triangle), the
second promoter of DLEU2 responsive to E2F1 and CMYC transcription factors (gray box),58,59 the minimal deleted region (gray arrow), U59
DLEU2 probe for copy number variation and gene expression analysis (black triangles) are shown. (b) Sequence of the genomic fragment
(1070 bp) analyzed for nucleotide variants in 249 CLL patients and cloned for exogenous expression analysis. Underlined the 187 bp sequence
investigated for transcription activity, copy number variation and RNA expression; the rs115069827 SNP is gray labeled; in bold and italic the
stem loops of the miR-15a and miR-16-1.
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and 11q deletion).31 Respective Spearman correlation factors (r)
for miR-15a and miR-16 were 0.55 (P¼ 0.0095) and 0.47 (P¼ 0.031)
for all the CLL cases; 0.83 (P¼ 0.0008) and 0.86 (P¼ 0.0003), for the
CLLs with the 13q deletion; conversely,  0.166 (P¼ 0.67) and
 0.3 (P¼ 0.43) for the CLLs with 11q deletion (Supplementary
Figure S3). This evidence further suggests that the miR-15a/16-1
has its own transcriptional activator in the immediate 50 flanking
region and that, according to CLL karyotype, its regulation is
related or unrelated to DLEU2 expression.
The SNP rs115069827 affects the maturation of miR-15a
As the SNP rs115069827 does not affect the strength of the newly
identified transcriptional activator, we investigated its role in the
processing of the miR-15a. We evaluated the expression of the
primiR and the miR-15a in PBMCs from CLL479 and CLL585 (both
heterozygous for rs115069827_SNP), from 5 CLL cases with
normal karyotype and from five healthy donors. Among these
samples, CLL479 showed the highest primiR expression level,
whereas the expressions of the mature forms of miR-15a and
miR-16 were significantly downregulated, in line with that of the
other CLLs (Figure 3a), according to the published data.4 In matched
samples, the median ratios between miR and primiR expression in
the CLLs and in the normal samples were respectively 0.002 and
0.028 (P¼ 0.017) for miR-15a, versus 1.72 and 8.34 for miR-16
(Figure 3b, Supplementary Table S1); hinting at a strong relevance
of impaired miR-15a/16-1 processing in CLL. The ratio for miR-15a
was even lower (0.00047) in CLL479, suggesting that in this
specific case, defective maturation was the main cause of miR-15a
downregulation. In this analysis, the expression of miR-16 was not
considered, as it is also transcribed by a different genomic locus.
Of note, CLL585, also positive for the SNP, showed a miR-15a/
primiR ratio similar to that of CLL479 (0.00076) (Supplementary
Table S1). CLL585 carries a homozygous deletion of the miR-15a/
16-1 locus in B cells and hence, the detected miR and primiR must
have originated from non-B cells. Taken together, these data
support the involvement of rs115069827SNP in the maturation
steps of miR-15a, in both leukemic and healthy cells. To
investigate this, we evaluated the expression of the mature form
Figure 2. The genomic region upstream the miR-15a and 16-1
cluster acts as promoter of transcription activity. (a) Relative
luciferase activity of the 187 bp genomic fragments harboring the
two variants of the SNP rs115069827 (pGL3Ren-187_A and 187_G)
after 24 h of transfection in HEK293 and MEC-02 cell lines. The
pGL3Ren empty vector was used as control. (b) Induction of primiR-
15a/16-1 expression in K562 and WaC3CD5 (WAC) cell lines after
24 h transfection of pCDF-1070A and pCDF-1070G vectors. RNAs
were previously treated with DNase to avoid genomic/plasmid
contamination that was further investigated by qPCR for the GFP
plasmid DNA fragment (data not shown). The primiR-15a/16-1
expression was normalized on the expression of the internal
reporter gene GFP. The pCDF vector used (SBI) is lacking of the
CMV promoter. The pCDF empty vector was used as control. P value
40.05 was considered not significant, between 0.01 to 0.05 (*)
significant, between 0.001 to 0.01 (**) very significant and o0.001
(***) extremely significant.
Figure 3. The minor allele of the SNP rs115069827 affect the
miR-15a maturation by impairing the primiR/Drosha binding
complex. (a) Expression analysis of primiR-15a/16-1 and mature
miR-15a in 7 CLL and five healthy donor (N) PBMC samples.
Data were normalized to RNU6B and RNU44 expression. (b) Graphics
represent the relative efficiency of maturation of miR-15a calculated
by the equation 2DCtmiR-15a/ 2DCtprimiR-15a/16-1. (c) qRT–PCR of the
mature form of miR-15a in K562 and WAC cell lines after 24 h of
transfection with the pCDF-1070_A/G vectors. (d) primiRNA 15a/
16-1 quantification of the IP RNA with the anti-DROSHA antibody in
K562 cells transfected with the pCDF-1070_A/G vectors (RIP). Data
were normalized on the primiRNA 15a/16-1 expression of the RNA
not IP (INPUT). Transfection efficiency was counted by GFP-positive
cells determined by fluorescence-activated cell sorting analysis.
P value40.05 was considered not significant, between 0.01 to 0.05
(*) significant, between 0.001 to 0.01 (**) very significant ando0.001
(***) extremely significant.
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of the miR-15a in K562 and WAC cells transfected with either
pCDF-1070_A or _G. In both cell lines, the expression of the miR-
15a from the vector with the G variant was lower than that from
the vector with the A variant (Figure 3c), in spite of the allele type
independent mode of expression of the exogenous primiR-15a/
16-1 (Figure 2b). For miR-16-1, similar results were obtained in
B cells derived from the transgenic CLL mouse model Em-TCL132
and infected with lentivirus particles transducing the 1070 bp
region with either the A or the G allele (Supplementary Figure S4).
SNPs in the flanking non-structured RNA sequences of microRNAs
can change the hairpin structures of the primiR, interfering with
the binding of proteins necessary for their processing to the
mature forms.5,33–37 Given that in mice the DEAD-box helicase
subunits of the Drosha complex (p68 and p72) are required for the
processing of primiR-15a/16-1 to mature miR-16-1,38 we evaluated
the efficiency of the interaction between the DROSHA complex
and the primiR-15a/16-1 in K562 cells transfected with the
pCDF-1070_A or _G vectors. By RIP analysis, the G allele showed
reduced DROSHA binding capacity when compared with the
A allele (Figure 3d).
RPIII is involved in the transcription of the primiR-15a/16-1
During the course of our experiments, we found that the 107 bp
region immediately upstream the miRNAs stem loops acts as
transcriptional activator of miR-15a/16-1 locus and is transcribed
as well. This is explainable considering either RPIII occupancy at
this region or a mechanism of transcription independent of the
RPI/RPII/RPIII, as recently described.39 We first investigated the
involvement of RPIII. We tested the primiR-15a/16-1 expression in
K562 cells transfected with either the pCDF_1070A/G vectors or
the control after treatment with the RPII inhibitor a-amanitin. The
left side of Figure 4a shows that the RPII takes part in the
transcription of the primiR-15a/16-1 derived from the
pCDF_1070A/G vectors. However, as these pCDF vectors hold an
RPII promoter (EF1, upstream the GFP reporter gene) we could not
exclude its influence at this region and/or a cooperation between
RPII and RPIII transcription.40,41 Therefore, we performed a similar
experiment after subcloning the 1070 bp fragments within the
pCR2.1 vector, to obtain pPCR2.1-1070 A/G vectors. We chose this
plasmid as it does not contain any eukaryotic promoters and/or
regulatory sequence. Treatment with a-amanitin significantly
reduced the endogenous ACTB pre-messenger RNA used as
control in the transfected cells (Supplementary Figure S5a), but
did not reduce the exogenous primiR-15a/16-1 expression
(Figure 4a), suggesting the existence of an RPII-independent
mechanism of transcription. Controls show that plasmid contam-
ination, although not completely removed, was very low and
irrelevant to the experimental results (Supplementary Figure S5b).
Similar results were observed by measuring the expression of the
miR-15a (Supplementary Figure S5c and d). To further support
RPIII involvement in primiR-15a/16-1 transcription, we silenced
two polymerase III subunits (POLR3A and POLR3G) in K562 cells, to
inhibit the RPIII activity. POLR3G is a specific subunit of the RPIII
complex, but its silencing does not prevent RPIII elongation,42
while POLR3A is specifically implicated in the elongation of the
RPIII transcripts.43 At 48 h from silencing, the cells were transfected
with the pCR2.1_1070_A vector to induce primiR transcription by
RPIII. Silencing of the POLR3A gene reduced the expression of the
primiR and of tRNAtyr (transcribed by RPIII), while the expression
of the ACTB pre-messenger RNA, transcribed by RPII, was not
affected; (Figure 4b). Moreover, by ChIP analysis, we also observed
slight binding of RPIII to the new transcription activator region,
apparently independent of the SNP allele (Figure 4c). Finally, we
performed ChIP analysis with the RPIII RPC32 subunit on the
MEC-1 B-CLL cell line24 transfected with the pCDF_1070_A vector
and treated or not with a-amanitin. Given that the pCDF_1070 s
vectors drive primiR-15a/16-1 expression by RPII (Figure 4a), we
tested RPIII occupancy after inhibition of RPII transcription. We
registered twofold primiR-15a/16-1 DNA enrichment only in cells
treated with a-amanitin (Figure 4d). A similar experiment was
conducted in K562 cells by measuring the endogenous primiR-15a/
16-1 expression. K562 cells harbor a monoallelic 13q deletion
and show RPII-dependent transcription of primiR-15a/16-1
(Supplementary Figure S6d). The ChIP analysis shows a primiR-15a/
16-1 DNA enrichment only in K562 cells treated with a-amanitin
(Figure 4e). These results confirm RPIII involvement in a different cell
line and support the participation of RPIII in primiR-15a/16-1
transcription only when RPII activity is prevented or inhibited.
Allele-specific transcription of primiR-15a/16-1
To assess the existence of an RPII-independent mechanism at the
candidate region in CLL patients, we evaluated the expression of
the primiR-15a/16-1 in PBMCs from CLL patients upon a-amanitin
treatment. To evaluate one allele at the time, we chose a subset of
31 cases (48% of the total analyzed patients) in which the 13q
region showed macrodeletions (by FISH) and/or microdeletions
(by copy number variation analysis of the DLEU2/miR-15a/16-1
region, Supplementary Table S2, Supplementary Figure S1b).
Regulation of primiR-15a/16-1 was respectively scored as RPII
dependent, in the samples that upon treatment shared a trend
similar to that of preACTB and/or preGAPDH and opposite to that
of the tRNAtyr gene, or RPIII-dependent, in the samples where
primiR expression was either unchanged or increased after
a-amanitin treatment (Supplementary Figure S6). Twenty out of
31 samples were informative on the basis of technical controls.
The results showed that in 8/20 cases (40%), the regulation of
primiR-15a/16-1 was RPIII-dependent, while in the other 12 cases
(60%) was driven by RPII (Table 2), suggesting that the two alleles
of this locus are differentially regulated. As we could not
distinguish whether the RPIII involvement arises from pathologic
and/or physiologic mechanisms, we decided to treat PBMCs from
the patient CLL585 with a-amanitin. This patient has a bi-allelic
deletion of the miR-15a/16-1 locus in B-CLL cells, but it still shows
heterozygosis of the SNP rs115069827 at both DNA and RNA
levels, likely arisen from the non-B cells. Therefore, a-amanitin is
predicted to affect only the ‘normal’ non-B PBMC population. By
sequencing, we demonstrated selective and progressive inhibition
of the expression of the A allele in an a-amanitin dose-dependent
manner, while the expression of the G allele was unchanged
(Figure 5). Overall, these data support allele-specific regulation of
the primiR-15a/16-1: one allele is most likely controlled by the
DLEU2 promoter/s, whereas transcription of the other allele occurs
through the recruitment of RPIII to the newly identified transcrip-
tion activator region.
Allele-specific transcription of primiR-15a/16-1 is associated with
ZAP70 expression in CLL
In the tested cases, we noted that the newly identified RPIII-
dependent mechanism predominated in CLLs with high expres-
sion of ZAP70 (Fisher’s exact test P¼ 0.019). Indeed, most of the
samples with high ZAP70 (6 out of 8) showed transcription of the
primiR-15a/16-1 by RPIII, conversely in the cases negative for
ZAP70, primiR-15a/16-1 transcription was mostly regulated by RPII
(10 out of 12 CLL patients) (Table 2, Supplementary Figure S6).
Notably, we had informative monozygotic twins with different
clinical course of the disease: CLL3tw, aggressive, and CLL4tw,
indolent (Supplementary Table S3). CLL cells from these twins
were immortalized and treated with a-amanitin. Upon treatment,
we noted transcription of the primiR-15a/16-1 respectively
mediated by RPIII in cells from CLL3tw (aggressive CLL) and by
RPII in cells from CLL4tw (indolent CLL) (Supplementary Figure
S6b, Table 2). To evaluate at molecular level the differences
between B-CLL cells in which the mir-15a/16-1 cluster is
transcribed by RPII versus RPIII, we measured the levels of
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miR-15a, primiR-15a/16-1 as well as TP53, BCL2 and Cyclin E
proteins, direct targets of miR-15a, in our B-purified CLL samples.
Although we did not find changes in the expression of primiR-
15a/16-1 and/or miR-15a (data not shown), we registered
differences in the protein levels of BCL2, TP53 and Cyclin E
with decreasing trend in the CLL samples in which the primiR-
15a/16-1 was transcribed by RPIII (Supplementary Figure S7);
suggesting that RNPII/RNPIII regulation of miR-15a/16-1 affects
the target genes. Considering ZAP70 status, a similar trend
was observed only for TP53, while for BCL2 the protein levels
were differently distributed between the two groups (F-test,
P¼ 0.0014).
In our survey (training set n¼ 36, validation set n¼ 18)
there were samples with 13q deletions that did not include
the miR-15a/16-1 locus. Almost all of these cases showed high
expression of ZAP70 (Fisher’s exact test: training set Po0.001;
validation set P¼ 0.006; Supplementary Table S2) and, in those
whose cells were available, despite the presence of both
alleles of miR-15a/16-1, we detected a RPIII-dependent
primiR regulation. Therefore, we performed copy number
Figure 4. RPIII is involved in the transcription of primiR-15a/16-1. (a) PrimiR-15a/16-1 expression in K562 cells transfected with the pCDF1070_A/G
(left side) and pCR2.1_1070_A/G vectors (right side) with and without a-amanitin treatment (2mg/ml). (b) PrimiR-15a/16-1, preACTB, tRNAtyr,
POLR3A and POLR3G relative expression (normalized on 18S expression) in K562 cells silenced for polymerase III subunits (POLR3A, POLR3G) and
then transfected with the pCR2.1_1070_A vector. (c) ChIP analysis for RPIII occupancy in the primiR-15a/16-1 and tRNAtyr (as control) DNA regions
by qPCR in K562 cells transfected with pCR2.1_1070_A/G vectors. Controls are represented by the pCR2.1 Empty vector (e) and the non-specific
unconjugated rabbit polyclonal antibody immunoglobulin G IP. Pre 15-16 and Pri 15-16 are two different genomic DNA fragments of the miR-
15a/16-1 cluster region (Supplementary Table S4). (d) ChIP analysis for RPIII occupancy in the primiR-15a/16-1 DNA region by qPCR in MEC-1 cells
transfected with pCDF_1070_A vector with and without a-amanitin treatment. Controls are represented by the non-specific unconjugated rabbit
polyclonal antibody immunoglobulin G IP and as there is not primiR-15a/16-1 DNA enrichment in the non a-amanitin-treated MEC-1 cells, the
amplification of the DNA IP with RPIII could be considered a specific signal. (e) ChIP analysis for RPIII occupancy in the primiR-15a/16-1 and
tRNAtyr (as control) DNA regions by PCR in nontransfected K562 cell line. P value40.05 was considered not significant, between 0.01 to 0.05 (*)
significant, between 0.001 to 0.01 (**) very significant and o0.001 (***) extremely significant.
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variation analysis of a more telomeric DNA region (B30 kb, U59
DLEU2 region), that encompasses the second DLEU2 promoter.
We found monoallelic deletion of this region, resulting in the
loss of the primiR regulation by the RPII-dependent DLEU2
promoter.
The molecular model of the DLEU2/miR-15a/16-1 locus we
propose is recapitulated in Figure 6, that illustrates the genetic
characteristics and their associations with ZAP70 status.
DISCUSSION
The minimal deleted region of 13q14 starts about 20 kb upstream
to the cluster encompassing the second DLEU2 promoter3,44 and
most genes localized in this critical region are downregulated by a
factor 42 in the CLLs with monoallelic 13q14 deletions. The miR-
15a/16-1 cluster is located within the DLEU2 gene and, monoallelic
DLEU2 expression has so far been demonstrated in 20–40% of B
and T cells from healthy donors,19 suggesting that there could
normally be monoallelic expression of the miR cluster as well. As
miR-15a and miR-16-1 are strongly implicated in the pathogenesis
of the disease,14–17 we aim to clarify the transcriptional regulation
of the miR-15a/16-1 cluster in CLL. Here, we demonstrate that the
transcription of the cluster is regulated simultaneously by
alternative mechanisms that use either RPII or RPIII in allele-
specific manner. The loss of the transcriptional regulation of
primiR-15a/16-1 by RPII is associated with high expression of
ZAP70, a poor prognostic feature of CLL patients.
We reached these results through characterization of the SNP
rs115069827, identified in two CLL patients at about 100 bp
upstream the miR-15a stem loop, able to abrogate the maturation
of the primiR-15a/16-1. This SNP is epidemiologically irrelevant for
Table 2. PrimiR-15a/16-1 transcritption by RPII-independent mechanism correlates with ZAP70 expression in 13q-deleted CLLs
Abbreviations: 12tri, 12 trisomy; 13q, deletion of 13q chromosome region; 17p, deletion of the 17p chromosome region; þ /þ , presence of both alleles;
þ / , monoallelic deletion; —, ZAP70p20%; þ , ZAP70420%; —, not determined; m, upregulation of RNA expression after a-amanitin treatment;
k, downregulation of RNA expression after a-amanitin treatment; ¼ , no change in the RNA expression after a-amanitin treatment; II, RPII; III, RPIII; CLL, chronic
lymphocytic leukemia; CNV, copy number variation; EBV, Epstein–Barr virus NK, normal karyotype. aCLL4Tw and CLL3Tw are CLL cell lines from monozygotic
twins immortalized with EBV that determines a reduced expression of the CD5.60 Samples more sensitive to the a-amanitin were analyzed at increasing
compound concentration, (see Supplementary Figure S6). Bold black symbols (m,k,¼ ) in the columns labeled ‘primiR-15a/16-1’, ‘tRNAtyr’ and ‘preACTB
or preGAPDH’ indicate the expression trend of the specific gene at the informative a-amanitin concentration (light gray symbols are not informative).
Fisher’s test: RPIII versus ZAP70, P¼ 0.019.
Figure 5. Allele-specific expression of the primiR-15a/16-1 in CLL585.
(a) PBMC from CLL585 were treated with a-amanitin at 2 and 10mg/ml
for 17h. The arrow indicates the variant A–G that shows dose-
dependent downregulation of the minor allele G after the a-amanitin
treatment. (b) primiR-15a/16-1 relative expression in CLL585 normal-
ized on the 18S expression (RNAPI) after a-amanitin treatment.
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CLL, because of its rarity, but allowed us to demonstrate
the existence of allele-specific effects on the transcription and,
consequently, the expression of miR-15a. In fact, the chromosome
region immediately upstream the miR cluster, once isolated from
other eukaryotic regulatory elements, was able to promote
RNA transcription by an RPII-independent, allele-exclusive and
RPIII-engaging mechanism. This novel mechanism is consistent
with the results of an independent study demonstrating
that the primiR-15a/16-1 RNA may or may not present
the characteristic RPII 50cap structure.45 RPIII-dependent
transcription of the miR-15a/16-1 cluster and defective miR
processing are unmasked in an allele-specific manner by the
13q14 deletion.
RPII and RPIII share several transcriptional elements,40,46,47 but it
is well known that there are important differences in their
transcriptional regulation.48 Increase in RPIII activity has been
observed in cancers.49 Moreover, RPIII activity is linked to the
transcription factors MYC, P53 and RB1,50–52 whose deregulation
have been associated with poor prognosis in several cancers,
including CLL.53–55,12 These genes control cell cycle and apoptosis
in concert with miR-15a/16-1.50–52,56,57 Therefore, we sought to
determine the clinical correlations associated with RPII versus RPIII
regulation of the miR cluster in our case series. Although the
follow up did not allow direct prognostic correlations, we
identified a significant association between RPIII-dependent
regulation of primiR-15a/16-1 and high expression of ZAP70, a
predictor of poor prognosis in CLL.22 Notably, we analyzed a rare
case of familial CLL in monozygotic twins that differed in ZAP70
status and clinical features (aggressive versus indolent disease).22
Transcription of primiR-15a/16-1 was driven by RPIII in the
aggressive ZAP70-positive CLL patient, but by RPII in the
indolent and ZAP70-negative case. We also identified a
significant correlation between type of genomic deletion and
ZAP70 expression status: almost all the CLLs cases with 13q
deletions that retained two copies of the miR-15a/16-1 cluster, but
lacked a more telomeric region, showed high ZAP70 expression.
Higher miR-15a expression has previously correlated with ZAP70
positivity in CLLs.5 We found RPIII-dependent regulation of the
primiR in almost all ZAP70-positive cells, but no difference in miR-
15a expression between the RPII- and RPIII-dependent groups was
observed, probably because the majority of the patients in our
subset had an indolent disease at the time of analysis. However,
differences in the levels of P53, BCL2 and Cyclin E proteins,
key targets of miR-15a and miR-16-1, were observed between
CLL cells with RPIII- versus RPII-mediated transcription of the
primiR-15a/16-1.
In conclusion, both alleles of the miR-15a/16-1 cluster are
normally transcribed, one by RPII together with DLEU2, which is
often expressed monoallelically, the other one by RPIII, indepen-
dently of the host gene. Being the DLEU2/miR-15a/miR-16-1 locus
finely regulated by cell cycle-related transcription factors,15,44,58,59
loss of regulation by RPII due to 13q14 deletions should alter the
expression of miR-15a/miR-16-1 and, consequently, cell cycle and
apoptosis. Evidences shows that co-expression of DLEU2 and of
miR-15a/16-1 by RPII is repressed by CMYC and activated by
E2F1 and P53.15,44,58,59 In our model, this applies only to the
RPII-dependent allele, while the transcription of the primiR-15a/
16-1 from the RPIII-dependent allele could be activated by
CMYC and repressed by P53.49 Exclusive RPIII regulation of miR-
15a/16-1 could affect P53/miR-34/ZAP70 signaling,15 resulting,
over time, in ZAP70-positive B-CLL cells. Two genetic
characteristics associate with high ZAP70: (i), primiR expression
driven by RPIII; (ii), type of 13q deletion that retains both alleles of
the miR-15a/16-1 locus.
Figure 6. Model of transcriptional regulation of miR-15a/16-1 cluster. On the left, transcriptional regulation of miR-15a/16-1 in normal cells is
modeled. The miR-15a/miR-16-1 expression is driven by two different mechanisms specific for the two alleles. Allele A shows the transcription
of DLEU2 gene and therefore, the miR-15a/16-1 cluster by an RPII-dependent mechanism. Conversely, the allele B shows DLEU2 expression
epigenetically repressed and consequently the miR-15a/16-1 expression is driven by an RPII-independent mechanism. Immediately upstream,
the miR-15a, the newly identified transcriptional activator region engages the RPIII to start the transcription of the miR-15a/16-1 cluster. 13q
deletions in CLL patients (right side) lead to the expression of miR-15a/16-1 by RPII and/or RPIII, depending on the deleted allele. Deletion of
the region encompassing the miR stem loops on allele A occurs in ZAP70 and ZAP70þ CLL, whereas the deletion of allele B mostly occurs in
CLL patients with low ZAP70 expression. In our model, the expression of miR-15a/16-1 cluster in ZAP70þ CLLs is driven by RPIII by two
different deletions of the allele A: deletion of the stem loop cluster transcribed by RPII or deletion of the regulatory elements of the active
DLEU2 gene.
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The double allele-specific regulation of a miR-15a/16-1 driven
by either RPII or RPIII may provide the basis for understanding
the clinical heterogeneity of the CLL patients carrying 13q14
deletions, and exclusive RPIII-driven transcription of this miR
cluster may differentiate at the onset aggressive from indolent
forms of CLL.
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